

Bisphosphonate May Preserve Trabecular Bone

BY TIMOTHY F. KIRN
Sacramento Bureau

SAN DIEGO — Risedronate treatment preserved trabecular bone in patients with advanced medial compartment knee osteoarthritis, and at a high dose even appeared to build it, Christopher Buckland-Wright, Ph.D., said at the annual meeting of the American College of Rheumatology.

Despite the loss of cartilage, “high doses of risedronate appeared to protect joints against bone loss, and preserved the structure and integrity,” said Dr. Buckland-Wright, professor of radiologic anatomy at King’s College London.

If the results are confirmed by additional studies, perhaps bisphosphonate treatment will be used to delay the onset of the compartmental collapse in knees affected by osteoarthritis.

The higher dose of risedronate preserved bone among patients with progressive narrowing of the medial tibial compartment, judging from x-ray findings.

Dr. Buckland-Wright presented the results of an analysis of a multicenter, placebo-controlled trial involving three different doses of risedronate in knee osteoarthritis: 5 mg/day, 15 mg/day, and 50 mg once a week.

His analysis included 100 patients randomly selected from each of the four groups. These patients were selected from the entire 1,200-patient cohort, which included 300 participants in each of the four study arms. The structure and density of trabecular bone in the medial tibial compartment were examined using an x-ray technique developed by Dr. Buckland-Wright.

Overall, most of the patients had evidence of vertical and trabecular bone loss during the 2-year course of the study. But among those who had progressive narrowing of the joint space, risedronate at the higher two doses appeared to preserve bone.

Patients taking 15 mg/day had stabilizing of both vertical and horizontal trabeculae. In the patients taking 50 mg per week, horizontal trabeculae stabilized, and there was an increase in vertical trabeculae, according to Dr. Buckland-Wright.

The patients with progressive narrowing on placebo and on the 5-mg a day dose continued to have bone loss, and had a greater degree of bone loss than those without progressive narrowing during the trial, who had no evidence of benefit at any dose.

The study was sponsored by Procter & Gamble Pharmaceuticals Inc., Mason, Ohio.

Drug Lessened Disease Severity

Methotrexate from page 1

above 2.4; at 12 months, the study medication was decreased by 5 mg every 4 weeks until discontinuation.

At 3 months, before dosage adjustments were made for DAS severity, the mean decrease in DAS was 0.39 in the

methotrexate and 0.005 in the placebo group, a difference that was statistically significant.

At 18 months, fewer patients in the methotrexate group had developed RA and more had achieved remission, compared with those in the placebo group (see chart).

Radiographic progression was significantly higher in the placebo group, noted Dr. van Dongen of Leiden (the Netherlands) University Medical Center.

This randomized clinical trial confirms the existence of a window of opportunity to prevent undifferentiated arthritis from evolving into RA, he wrote.

Status at 18 Months After Diagnosis of Undifferentiated Arthritis

	RA	UA	UA in Remission	OA	Lost to Follow-up
Methotrexate (n = 55)	20	13	18	1	3
Placebo (n = 55)	29	8	11	4	3

Source: Dr. van Dongen

Rheumatologists prescribe EVOXAC® (cevimeline HCl) more than any other secretory agonist*

Mouth-watering relief

EVOXAC® first line—proven relief for the dry-mouth symptoms of Sjögren’s syndrome

Patients treated with EVOXAC reported significant improvement for the following end points^{1-3†‡}:



Feeling of mouth
Dryness of mouth
Dryness of tongue



Ability to speak
without
drinking liquids



Ability to chew and
swallow food



Ability to sleep

EVOXAC®
(cevimeline HCl) 30 mg Capsules
('ē vō zak)
Proven Relief...
Proven Results

Safety considerations

- The most frequently reported adverse events associated with the pharmacologic action of a muscarinic agonist (>10% incidence) in clinical trials of cevimeline were: excessive sweating, nausea, rhinitis, and diarrhea. Consult the brief summary of prescribing information for other adverse events
- Cevimeline is contraindicated in patients with uncontrolled asthma, known hypersensitivity to the drug, and in acute iritis and narrow-angle (angle-closure) glaucoma
- Consult the brief summary of prescribing information for safety considerations concerning drug interactions, special populations, patients with a history of cardiac disease, controlled asthma, chronic bronchitis, COPD, nephrolithiasis, or cholelithiasis

Please see accompanying brief summary of prescribing information.

- Special care should be exercised when cevimeline is taken by geriatric patients, considering the greater frequency of decreased hepatic, renal, or cardiac function
- Cevimeline can potentially alter cardiovascular function. Consult the brief summary of prescribing information concerning these potential effects
- Caution should be advised while driving at night or performing hazardous activities in reduced lighting

*IMS Health. National Prescription Audit Plus™ for the 6-month period ending March 2004.

† In 1 or more clinical trials, patients reported significant improvement for these secondary end points at various measurement intervals using a visual analogue scale (VAS) (PA0.05).

‡ Statistical significance was not observed consistently for every secondary end point at each point of measurement across all studies.

For more information about EVOXAC, visit www.evoxac.com